Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 2:48 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Aripiprazole IM Depot Clear all
Completed Phase 1 Interventional Results available

Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole

NCT01552772
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Anaheim, California • Cerritos, California • Garden Grove, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2014 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 3 Interventional Results available

Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia

NCT01683058
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 66 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Carson, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2015 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00705783
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole depot, Placebo depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
43
States / cities
Chandler, Arizona • Anaheim, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 3 Interventional Results available

Open-label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder

NCT01710709
View directory record Official record
Conditions
Bipolar I
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
72
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 3 Interventional Results available

Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in the Acute Treatment of Adults With Schizophrenia

NCT01663532
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
43
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 1 Interventional Results available

Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia

NCT01909466
View directory record Official record
Conditions
Schizophrenia, Mental Disorder, Nervous System Diseases
Interventions
Aripiprazole, OPC-14597
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
11
States / cities
Cerritos, California • Garden Grove, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2015 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 3 Interventional Results available

An Open-Label, Multicenter, Rollover, Long-term Study of Aripiprazole Intramuscular Depot in Participants With Schizophrenia

NCT01129882
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
52
States / cities
Bellevue, California • Garden Grove, California • Glendale, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00706654
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole depot 300 or 400 mg, Aripiprazole 10-30 mg orally, Aripiprazole depot 25 or 50 mg, Placebo depot, Placebo tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
937 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
39
States / cities
Cerritos, California • Escondido, California • Garden Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 1 Interventional Results available

A Multiple Dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot

NCT01870999
View directory record Official record
Conditions
Schizophrenia
Interventions
aripiprazole IM depot, aripiprazole tablets
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
7
States / cities
Cerritos, California • Garden Grove, California • Glendale, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 1Phase 2 Interventional Results available

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 Disorder

NCT04030143
View directory record Official record
Conditions
Schizophrenia, Bipolar I Disorder
Interventions
Aripiprazole
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 3 Interventional Results available

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

NCT00731549
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
96
States / cities
Chandler, Arizona • Anaheim, California • Cerritos, California + 78 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 3 Interventional Results available

Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole

NCT01432444
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole (Abilify®) IM Depot Injection
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
119
States / cities
Dothan, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 97 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 1 Interventional Results available

An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia

NCT01646827
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole IM Depot
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Cerritos, California • Garden Grove, California • San Diego, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Nov 1, 2026, 2:48 AM EST
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients

NCT01567527
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Intramuscular (IM) Depot Aripiprazole, Intramuscular (IM) Depot Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
731 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
42
States / cities
Birmingham, Alabama • Springdale, Arkansas • Beverly Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Nov 1, 2026, 2:48 AM EST